A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Abstract Text:

Y D Lapierre,N P Nair,G Chouinard,A G Awad,B Saxena,B Jones,D J McClure,D Bakish,P Max,R Manchanda,

The efficacy and side-effect profile for three dose ranges of remoxipride were compared with haloperidol in 242 schizophrenic inpatients in 13 centres. All patients were in a productive phase of schizophrenia according to DSM-III criteria. Relative efficacy of low dose (30-90 mg daily) vs middle dose (120-240 mg daily) vs high dose (300-600 mg daily) was compared with the standard dose of haloperidol (15-45 mg daily), as were the side effects. It was concluded that the therapeutic efficacy of remoxipride was comparable to that of haloperidol for acute episodes of schizophrenia; that the low dose range was significantly less effective than the higher ranges; that there was a clear advantage of remoxipride over haloperidol with respect to incidence and severity of extrapyramidal symptoms. The general safety profile of remoxipride as assessed from clinical chemistry, haematology, and cardiovascular variables suggests that remoxipride in the dose ranges studied can be used safely for the treatment of schizophrenic patients.

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Publishing Authors By Initials

YD Lapierre,NP Nair,G Chouinard,AG Awad,B Saxena,B Jones,DJ McClure,D Bakish,P Max,R Manchanda,

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 358

Page Numbers: 72-7

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1990

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Information

Substance Name: Remoxipride

Registry Number: 80125-14-0

Grant and Affiliation Information for A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.

AFFILIATION: Royal Ottawa Hospital, Ottawa, Ontario, Canada.

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial Related Publications

• A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
• Arsenical encephalopathy.
• Congenital cystic adenomatoid malformation of lung--differential diagnosis and management.
• Effect of barium on diffusion of sodium in borosilicate glass.
• Effects of heptanol and carbenoxolone on noradrenaline induced contractions in guinea pig vas deferens.
• Optode for uranium(VI) determination in aqueous medium.